Dengue Vaccine Live
Dengue vaccine live is a live, attenuated virus vaccine.
Uses for Dengue Vaccine Live
Dengue vaccine live has the following uses:
Dengue vaccine live is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. Dengue vaccine live is approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
Dengue vaccine live has the following limitations of use:
Dengue vaccine live is not approved for use in individuals not previously infected by any dengue virus serotype or for whom this information is unknown. Those not previously infected are at increased risk for severe dengue disease when vaccinated and subsequently infected with dengue virus. Previous dengue infection can be assessed through a medical record of a previous laboratory-confirmed dengue infection or through serological testing prior to vaccination.
The safety and effectiveness of dengue vaccine live have not been established in individuals living in dengue nonendemic areas who travel to dengue endemic areas.
Dengue Vaccine Live Dosage and Administration
Dengue vaccine live is available in the following dosage form(s) and strength(s):
Suspension for injection (0.5 mL) supplied as a lyophilized powder to be reconstituted with the supplied diluent.
It is essential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Three doses (0.5 mL each) 6 months apart (at month 0, 6, and 12).
Cautions for Dengue Vaccine Live
A history of severe allergic reaction to a previous dose of dengue vaccine live or to any component of dengue vaccine live.
Increased Risk of Severe Dengue Disease Following Dengue Vaccine Live in Persons Not Previously Infected with Dengue Virus
In unvaccinated individuals, first dengue infections rarely cause severe dengue disease, while second dengue infections with a different serotype are associated with an increased risk of severe dengue disease. Dengue vaccine live administration to individuals not previously infected by dengue virus is associated with an increased risk of severe dengue disease when the vaccinated individual is subsequently infected with any dengue virus serotype. Therefore, healthcare professionals must evaluate individuals for prior dengue infection to avoid vaccinating individuals who have not been previously infected by dengue virus.
Previous infection by dengue virus can be evaluated through a medical record of previous laboratory-confirmed dengue infection or through serotesting prior to vaccination.
There is no FDA cleared test available to determine a previous dengue infection. Available non-FDA cleared tests may yield false positive results (e.g., due to cross-reactivity with other flaviviruses).
Management Of Acute Allergic Reactions
Dengue vaccine live may cause hypersensitivity reactions, including anaphylaxis. Appropriate medical treatment and supervision must be available following administration of dengue vaccine live.
Limitations of Vaccine Effectiveness
Vaccination with dengue vaccine live may not protect all individuals. It is recommended to continue personal protection measures against mosquito bites after vaccination.
Syncope (fainting) can occur following, or even before, vaccination with dengue vaccine live as a psychogenic response to injection with a needle. Procedures should be in place to prevent injury from falling and to manage syncopal reactions.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to dengue vaccine live during pregnancy. Women who receive dengue vaccine live during pregnancy are encouraged to contact directly, or have their healthcare professional contact, Sanofi Pasteur Inc. at 1-800-822-2463 (1-800-VACCINE) to enroll in or obtain information about the registry.
Risk Summary: All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
No specific studies of dengue vaccine live have been performed among pregnant women. A limited number of cases of inadvertent exposure during pregnancy were reported during clinical studies. Isolated adverse pregnancy outcomes (e.g., stillbirth, intrauterine death, spontaneous abortion, blighted ovum) have been observed for these exposed pregnancies, with similar frequency and nature in the vaccinated individuals compared to the control group, and with risk factors identified for all cases. Available data in pregnant women are not sufficient to determine the effects of dengue vaccine live on pregnancy, embryo-fetal development, parturition and postnatal development.
In two developmental toxicity studies, the effect of dengue vaccine live on embryo-fetal and postnatal development was evaluated in pregnant rabbits and mice. A developmental toxicity study was performed in female rabbits given a 5 log1050% cell culture infectious dose (CCID50) of dengue vaccine live (full human dose ranging from 4.5 log10 to 6.0 log10 CCID50) by intravenous injection prior to mating and during gestation. The study revealed no evidence of harm to the fetus due to dengue vaccine live. In another study, female mice were administered a single dose of 5 log10 CCID50, 6.5 log10 CCID50 (about 3 times the highest human dose) or 8 log10 CCID50 (about 100 times the highest human dose) of dengue vaccine live by intravenous injection during gestation. Fetal toxicities were observed at maternally toxic doses.
Clinical Considerations: Pregnant women are at increased risk of complications associated with dengue infection compared to non-pregnant women. Pregnant women with dengue infection may be at increased risk for adverse pregnancy outcomes, including preterm labor and delivery. Vertical transmission of dengue virus from mothers with viremia at delivery to their infants has been reported.
Vaccine viremia can occur 7 to 14 days after vaccination with a duration of <7 days. The potential for transmission of the vaccine virus from mother to infant is unknown.
Animal Data: In two developmental toxicity studies, the effect of dengue vaccine live on embryo-fetal and postnatal development was evaluated in pregnant rabbits and mice.
Rabbits were administered a full human dose [0.5 mL (5 log10 CCID50/animal/occasion)] of dengue vaccine live by intravenous injection 30 and 10 days before mating and on Days 6, 12 and 27 during gestation. No vaccine-related fetal malformation or variations and adverse effects on female fertility or preweaning development were reported in this study. Pregnant mice were administered a single dose of either 5 log10 CCID50 (full human dose ranging from 4.5 log10 to 6.0 log10 CCID50), 6.5 log10 CCID50 (about 3 times the highest human dose) or 8 log10 CCID50 (about 100 times the highest human dose) of dengue vaccine live by intravenous injection on Day 6, 9 or 12 of gestation. At doses of 6.5 log10 CCID50 or 8 log10 CCID50 of dengue vaccine live, maternal toxicity was observed which was associated with increased postimplantation loss and at doses of 8 log10 CCID50 with reduced fetal body weight. The significance of this observation for humans is unknown, especially considering the different route of administration (the human route of administration is subcutaneous) and dose levels which exceeded the intended human dose. There were no vaccine related fetal malformations or other evidence of teratogenesis noted in this study.
Risk Summary: Human data are not available to assess the impact of dengue vaccine live on milk production, its presence in breast milk, or its effects on the breastfed child. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for dengue vaccine live and any potential adverse effects on the breastfed child from dengue vaccine live or from the underlying maternal condition. For preventive vaccines, the underlying condition is susceptibility to disease prevented by the vaccine. A lactation study in which female mice were administered a single dose of dengue vaccine live on day 14 of lactation did not show the presence of dengue vaccine live in breast milk.
Clinical Considerations: Vertical transmission of dengue virus, including potentially through breastmilk, has been reported.
Vaccine viremia can occur 7 to 14 days after vaccination with a duration of <7 days. The potential for transmission of the vaccine virus from mother to infant through breastmilk is unknown.
Animal Data: A developmental toxicity study in which female mice were administered a single injection of 5 log10 CCID50 (full human dose ranging from 4.5 log10 to 6.0 log10 CCID50), 6.5 log10 CCID50 or 8 log10 CCID50 of dengue vaccine live by intravenous injection on Day 14 of lactation did not show the presence of dengue vaccine live in breast milk in mice when measured 24 hours after vaccine administration.
Safety and effectiveness of dengue vaccine live in children younger than 9 years of age have not been established.
Safety and effectiveness of dengue vaccine live in adults 65 years of age and older have not been established.
Common Adverse Effects
The most frequently reported adverse reactions regardless of the dengue serostatus prior to vaccination were headache (40%), injection site pain (32%), malaise (25%), asthenia (25%), and myalgia (29%).
It is essential that the manufacturer's labeling be consulted for more detailed information on interactions with this drug, including possible dosage adjustments. Interaction highlights:
False negative tuberculin purified protein derivative (PPD) test results may occur within 1 month following vaccination with dengue vaccine live.
Mechanism of Action
Following administration, dengue vaccine live elicits dengue-specific immune responses against the four dengue virus serotypes. The exact mechanism of protection has not been determined.
Advice to Patients
Patient Counseling Information
Educate vaccine recipients regarding the most common adverse reactions that occur within 14 days following administration of dengue vaccine live (headache, injection site pain, malaise, asthenia, and myalgia).
Inform individuals to seek medical care if they develop signs and symptoms of dengue fever with particular attention to severe dengue warning signs (e.g., high fever, severe abdominal pain or tenderness, persistent vomiting, mucosal bleeding, somnolence and hyperactivity).
Register women who receive dengue vaccine live during pregnancy in the Pregnancy Registry by calling 1-800-822- 2463 (1-800-VACCINE).
Instruct vaccine recipients to report adverse reactions to their healthcare provider.
AHFSfirstRelease™. For additional information until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is essential that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
For Injection, for subcutaneous use
4.5–6 log10 CCID50 (50% cell culture infectious dose) each of chimeric yellow fever dengue (CYD) virus serotypes 1, 2, 3, and 4 per 0.5 mL
Sanofi Pasteur Inc.
AHFS Drug Information. © Copyright 2021, Selected Revisions September 2, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.